Clinical trial
Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients
Name
2222018NCRRT
Description
To evaluate the effect of human amniotic membrane as a weekly dressing on chronic wounds in Epidermolysis Bullosa (EB) patients.
Trial arms
Trial start
2017-01-01
Estimated PCD
2017-12-01
Trial end
2019-02-01
Status
Completed
Treatment
REGE pro dressing
REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
Arms:
Treated
Size
8
Primary endpoint
Lesion area
6 weeks
Clinical progression sings
6 weeks
Eligibility criteria
Inclusion Criteria:
1- Patients diagnosed as EB wounds must be chronic
Exclusion Criteria:
1. Patients Must stop other line of treatment
2. Exclude patients have:
1. Autoimmune diseases
2. Diabetes
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 8, 'type': 'ACTUAL'}}
Updated at
2023-09-21
1 organization
1 product
2 indications
Organization
Egyptian Atomic Energy AuthorityProduct
REGE proIndication
Epidermolysis BullosaIndication
Chronic Skin Ulcer